[P68] Poster Session 68　Clinical Trial Facilitation Program

[P68-2] KontRASt-01: A Phase Ib/II, open-label, dose-escalation study of JDQ443 in pts with adv. KRAS G12C-mutated solid tumors

^○Toshio Shimizu¹, Benjamin Solomon², Daniel Sw Tan³, Philippe A Cassier⁴, Christophe Dooms⁵, Eric Van Cutsem⁶, Conor E Steuer⁷, Neeltje Steeghs⁸, Martin Schuler⁹, Anas Gazzah¹⁰, Martin Wermke¹¹, Enriqueta Felip¹², Herbert Hf Loong¹³, Maria J De Miguel Luken¹⁴, Ashley Jaeger¹⁵, Kun Xu¹⁶, Xiaoming Cui¹⁶, Heather Burks¹⁵, Anna F Farago¹⁵, Rebecca S Heist¹⁷ (1.National Cancer Center Hospital, Tokyo, Japan, 2.Peter MacCallum Cancer Center, Melbourne, Australia, 3.National Cancer Centre Singapore, Singapore, 4.Centre Léon Bérard, Lyon, France, 5.UZ Leuven University Hospital, Leuven, Belgium, 6.University Hospitals Gasthuisberg, Leuven and KU Leuven, Leuven, Belgium, 7.Winship Cancer Institute of Emory University School of Medicine, Georgia, GA, USA, 8.The Netherlands Cancer Institute, Amsterdam, the Netherlands, 9.West German Cancer Center, University Hospital Essen, Essen, Germany, 10.Institut Gustave Roussy, Villejuif, France, 11.Technical University Dresden, NCT/UCC Early Clinical Trial Unit, Dresden, Germany, 12.Vall d’Hebron University Hospital, Barcelona, Spain, 13.Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong, 14.Hospital Universitario HM Sanchinarro, Madrid, Spain, 15.Novartis Institutes for BioMedical Research, Cambridge, MA, USA, 16.Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 17.Massachusetts General Hospital, Boston, MA, USA)